Porosome Therapeutics Inc. is a Boston-based biopharmaceutical company utilizing breakthrough discovery and novel technologies to identify and create patent-pending high-value therapeutics for currently undruggable porosome protein and lipid targets relating to secretory and hydration disorders such as cystic fibrosis, diabetes, and cancer. Porosome Therapeutics is the first company with a technology platform that develops novel therapies targeting the porosome, the universal cellular structure controlling secretion. This platform is based on decades of research supported by more than 200 publications and is effective against many serious diseases involving secretory defects. The platform also specializes in highly specific disease-targeting that yields superior therapies and a reduction or elimination of side effects